Publications
CancerGuide’s unique approach to molecular diagnostic testing is being developed and validated in the lab. Several controlled studies are underway and the results of which will be published and made available for your review.
CancerGuide’s executive management has been actively commercializing diagnostic technologies for two decades. Several of the more recent publications are listed below:
HLA-B*5701 clinical testing: early experience in the United States.
HLA-B*5701 screening for hypersensitivity to abacavir
Abacavir Hypersensitivity: A Model System for Pharmacogenetic Test Adoption